TY - JOUR
T1 - Complement Activation During lschemia/Reperfusion Injury Induces Pericyte-to-Myofibroblast Transdifferentiation Regulating Peritubular Capillary Lumen Reduction Through pERK Signaling
AU - Castellano, Giuseppe
AU - Franzin, Rossana
AU - Stasi, Alessandra
AU - Divella, Chiara
AU - Sallustio, Fabio
AU - Pontrelli, Paola
AU - Lucarelli, Giuseppe
AU - Battaglia, Michele
AU - Staffieri, Francesco
AU - Crovace, Antonio
AU - Stallone, Giovanni
AU - Seelen, Marc
AU - Daha, Mohamed R.
AU - Grandaliano, Giuseppe
AU - Gesualdo, Loreto
PY - 2018/5/23
Y1 - 2018/5/23
N2 - Pericytes are one of the principal sources of scar-forming myofibroblasts in chronic kidneys disease. However, the modulation of pericyte-to-myofibroblast transdifferentiation (PMT) in the early phases of acute kidney injury is poorly understood. Here, we investigated the role of complement in inducing PMT after transplantation. Using a swine model of renal ischemia/reperfusion (I/R) injury, we found the occurrence of PMT after 24 h of I/R injury as demonstrated by reduction of PDGFR beta(+)/NG2(+) cells with increase in myofibroblasts marker alpha SMA. In addition, PMT was associated with significant reduction in peritubular capillary lumina! diameter. Treatment by C1-inhibitor (C1-INH) significantly preserved the phenotype of pericytes maintaining microvascular density and capillary lumen area at tubulointerstitial level. In vitro, C5a transdifferentiated human pericytes in myofibroblasts, with increased alpha SMA expression in stress fibers, collagen I production, and decreased antifibrotic protein Id2. The C5a-induced PMT was driven by extracellular signal-regulated kinases phosphorylation leading to increase in collagen I release that required both non-canonical and canonical TGF beta pathways. These results showed that pericytes are a pivotal target of complement activation leading to a profibrotic maladaptive cellular response. Our studies suggest that C1-INH may be a potential therapeutic strategy to counteract the development of PMT and capillary lumen reduction in I/R injury.
AB - Pericytes are one of the principal sources of scar-forming myofibroblasts in chronic kidneys disease. However, the modulation of pericyte-to-myofibroblast transdifferentiation (PMT) in the early phases of acute kidney injury is poorly understood. Here, we investigated the role of complement in inducing PMT after transplantation. Using a swine model of renal ischemia/reperfusion (I/R) injury, we found the occurrence of PMT after 24 h of I/R injury as demonstrated by reduction of PDGFR beta(+)/NG2(+) cells with increase in myofibroblasts marker alpha SMA. In addition, PMT was associated with significant reduction in peritubular capillary lumina! diameter. Treatment by C1-inhibitor (C1-INH) significantly preserved the phenotype of pericytes maintaining microvascular density and capillary lumen area at tubulointerstitial level. In vitro, C5a transdifferentiated human pericytes in myofibroblasts, with increased alpha SMA expression in stress fibers, collagen I production, and decreased antifibrotic protein Id2. The C5a-induced PMT was driven by extracellular signal-regulated kinases phosphorylation leading to increase in collagen I release that required both non-canonical and canonical TGF beta pathways. These results showed that pericytes are a pivotal target of complement activation leading to a profibrotic maladaptive cellular response. Our studies suggest that C1-INH may be a potential therapeutic strategy to counteract the development of PMT and capillary lumen reduction in I/R injury.
KW - complement system
KW - pericytes
KW - ischemia-reperfusion
KW - tubulointerstitial fibrosis
KW - capillary rarefaction
KW - C1-inhibitor
KW - C5a
KW - ISCHEMIA-REPERFUSION INJURY
KW - ANTIBODY-MEDIATED REJECTION
KW - SERINE-PROTEASE INHIBITOR
KW - RENAL-ALLOGRAFT SURVIVAL
KW - MESENCHYMAL STEM-CELLS
KW - KIDNEY-TRANSPLANTATION
KW - C1 INHIBITOR
KW - TUBULOINTERSTITIAL FIBROSIS
KW - ESTERASE INHIBITOR
KW - EXPRESSION
U2 - 10.3389/fimmu.2018.01002
DO - 10.3389/fimmu.2018.01002
M3 - Article
SN - 1664-3224
VL - 9
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 1002
ER -